Market Cap
€3.2b
Last Updated
2019/10/19 20:45 UTC
Data Sources
Company Financials +
Executive Summary
Glanbia plc operates as a nutrition company worldwide.
Snowflake
Fundamentals
Adequate balance sheet average dividend payer.
Similar Companies
Share Price & News
How has Glanbia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.0%
GL9
-1.9%
IE Food
0.2%
IE Market
1 Year Return
-25.4%
GL9
12.9%
IE Food
4.3%
IE Market
Return vs Industry: GL9 underperformed the Irish Food industry which returned 12.9% over the past year.
Return vs Market: GL9 underperformed the Irish Market which returned 4.3% over the past year.
Shareholder returns
| GL9 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.0% | -1.9% | 0.2% |
| 30 Day | -2.1% | -2.2% | 5.9% |
| 90 Day | -24.1% | -0.06% | 2.3% |
| 1 Year | -24.0%-25.4% | 17.6%12.9% | 6.6%4.3% |
| 3 Year | -26.2%-29.4% | 33.5%14.3% | 18.0%12.4% |
| 5 Year | 3.6%-2.2% | 59.8%47.0% | 77.3%62.2% |
Price Volatility Vs. Market
How volatile is Glanbia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Glanbia plc (ISE:GL9) Excessively Paying Its CEO?3 weeks ago | Simply Wall St
Is Glanbia plc's (ISE:GL9) 2.2% Dividend Worth Your Time?1 month ago | Simply Wall St
Can Glanbia plc's (ISE:GL9) ROE Continue To Surpass The Industry Average?Valuation
Is Glanbia undervalued compared to its fair value and its price relative to the market?
34.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: GL9 (€10.95) is trading below our estimate of fair value (€16.62)
Significantly Undervalued: GL9 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: GL9 is good value based on its PE Ratio (14.8x) compared to the Food industry average (17.1x).
PE vs Market: GL9 is poor value based on its PE Ratio (14.8x) compared to the Irish market (13.8x).
Price to Earnings Growth Ratio
Low PEG Ratio: GL9 is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: GL9 is overvalued based on its PB Ratio (2x) compared to the XE Food industry average (1.2x).
Next Steps
Future Growth
How is Glanbia forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
7.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GL9's forecast earnings growth (7.5% per year) is above the savings rate (0.9%).
Earnings vs Market: GL9's earnings (7.5% per year) are forecast to grow slower than the Irish market (13% per year).
High Growth Earnings: GL9's earnings are forecast to grow, but not significantly.
Revenue vs Market: GL9's revenue (6.1% per year) is forecast to grow faster than the Irish market (4.2% per year).
High Growth Revenue: GL9's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: GL9's Return on Equity is forecast to be low in 3 years time (13.6%).
Next Steps
Past Performance
How has Glanbia performed over the past 5 years?
9.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: GL9's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: GL9's earnings growth over the past year (0.05%) is below its 5-year average (9.7% per year).
Earnings vs Industry: GL9 earnings growth over the past year (0.05%) underperformed the Food industry 0.3%.
Return on Equity
High ROE: GL9's Return on Equity (13.5%) is considered low.
Return on Assets
ROA vs Industry: GL9 has a higher Return on Assets than the Food industry average last year.
Return on Capital Employed
ROCE Improving: GL9's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Glanbia's financial position?
Financial Position Analysis
Short Term Liabilities: GL9's short term assets (€1.1B) exceeds its short term liabilities (€575.4M)
Long Term Liabilities: GL9's short term assets (1.1B) do not cover its long term liabilities (1.1B)
Debt to Equity History and Analysis
Debt Level: GL9's debt to equity ratio (59.9%) is considered high
Reducing Debt: GL9's debt to equity ratio has reduced from 80.6% to 59.9% over the past 5 years.
Debt Coverage: GL9's debt is well covered by operating cash flow (21%).
Interest Coverage: GL9's interest payments on its debt are well covered by EBIT (10.2x coverage).
Balance Sheet
Inventory Level: GL9 has a high level of physical assets or inventory.
Debt Coverage by Assets: GL9's debt is covered by short term assets (assets are 1.140350x debt).
Next Steps
Dividend
What is Glanbia's current dividend yield, its reliability and sustainability?
2.30%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: GL9's dividend (2.3%) isn’t notable compared to the bottom 25% of dividend payers in the Irish market (2.32%).
High Dividend: GL9's dividend (2.3%) is low compared to the top 25% of dividend payers in the Irish market (3.97%).
Stable Dividend: GL9's dividends per share have been stable in the past 10 years.
Growing Dividend: GL9's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (33.9%), GL9's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GL9's dividends in 3 years are forecast to be well covered by earnings (32.1% payout ratio).
Next Steps
Management
What is the CEO of Glanbia's salary, the management and board of directors tenure and is there insider trading?
4.7yrs
Average management tenure
CEO
Siobhán Talbot (55yo)
5.9yrs
Tenure
€2,341,000
Compensation
Ms. Siobhán Talbot, B.Comm., FCA has been the Group Managing Director of Glanbia plc since November 12, 2013 and its Executive Director since July 1, 2009. Ms. Talbot served as Group Finance Director at Gl ...
CEO Compensation Analysis
Compensation vs. Market: Siobhán's total compensation ($USD2.61M) is about average for companies of similar size in the Irish market ($USD1.49M).
Compensation vs Earnings: Siobhán's compensation has increased by more than 20% in the past year.
Management Age and Tenure
4.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: GL9's management team is considered experienced (4.7 years average tenure).
Board Age and Tenure
2.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: GL9's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: GL9 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Group Finance Director & Executive Director |
| Shares | 5,000 |
| Max Price | €9.84 |
| Entity | Individual |
| Shares | 2,500 |
| Max Price | €10.90 |
| Entity | Individual |
| Shares | 4,000 |
| Max Price | €11.53 |
| Entity | Individual |
| Shares | 1,000 |
| Max Price | €11.44 |
| Entity | Individual |
| Role | Chairman of the Board Chairman |
| Shares | 8,000 |
| Max Price | €11.52 |
| Entity | Individual |
| Role | Chief Executive Officer Group MD & Executive Director |
| Shares | 5,000 |
| Max Price | €11.15 |
| Entity | Individual |
| Role | Chief Executive Officer Group MD & Executive Director |
| Shares | 14,842 |
| Max Price | €17.29 |
| Entity | Individual |
| Role | Unit CEO Chief Executive Officer of Glanbia Nutritionals |
| Shares | 14,755 |
| Max Price | €17.45 |
| Entity | Individual |
| Role | Member of the Board of Directors Group Finance Director & Executive Director |
| Shares | 8,730 |
| Max Price | €17.29 |
| Entity | Individual |
| Role | Unit CEO Chief Executive Officer of Glanbia Performance Nutrition |
| Shares | 14,989 |
| Max Price | €17.39 |
| Entity | Individual |
| Role | Secretary Group Secretary |
| Shares | 4,718 |
| Max Price | €17.29 |
| Entity | Individual |
| Role | Unit CEO Chief Executive Officer of Glanbia Performance Nutrition |
| Shares | 8,535 |
| Max Price | €18.55 |
| Entity | Individual |
| Role | Secretary Group Secretary |
| Shares | 5,000 |
| Max Price | €18.45 |
| Entity | Individual |
| Role | Unit CEO Chief Executive Officer of Glanbia Nutritionals |
| Shares | 8,082 |
| Max Price | €18.54 |
Ownership Breakdown
Management Team
Mark Garvey (55yo)
Group Finance Director & Executive Director
- Tenure: 5.9yrs
- Compensation: €1.37m
Siobhán Talbot (55yo)
Group MD & Executive Director
- Tenure: 5.9yrs
- Compensation: €2.34m
Michael Patten (57yo)
Director of Group Human Resources & Corporate Affairs
- Tenure: 4.8yrs
Brian Phelan (52yo)
Chief Executive Officer of Glanbia Nutritionals
- Tenure: 0.8yrs
- Compensation: €1.19m
Michael Horan (54yo)
Group Secretary
- Tenure: 14.3yrs
Jim Bergin (56yo)
Chief Executive of Glanbia Ingredients Ireland Limited
- Tenure: 2.3yrs
Hugh McGuire (48yo)
Chief Executive Officer of Glanbia Performance Nutrition
- Tenure: 0.8yrs
- Compensation: €1.38m
Martha Kavanagh
Head of Corporate Communications
- Tenure: 0yrs
Tom Tench (48yo)
Group Corporate Development Director
- Tenure: 4.6yrs
Liam Hennigan
Group Director of Strategic Planning & Investor Relations
- Tenure: 0yrs
Board Members
Dan O'Connor (59yo)
Senior Independent Director
- Tenure: 0.4yrs
- Compensation: €95.00k
Mark Garvey (55yo)
Group Finance Director & Executive Director
- Tenure: 5.9yrs
- Compensation: €1.37m
Michael Walsh (76yo)
Member of the US Advisory Board
- Tenure: 0yrs
Siobhán Talbot (55yo)
Group MD & Executive Director
- Tenure: 5.9yrs
- Compensation: €2.34m
Eamon Power (64yo)
Non Executive Director
- Tenure: 2.3yrs
- Compensation: €43.00k
Donard Gaynor (62yo)
Independent Non-Executive Director
- Tenure: 6.6yrs
- Compensation: €95.00k
Martin Keane (63yo)
Chairman
- Tenure: 1.3yrs
- Compensation: €90.00k
Wayne Seltzer (76yo)
Member of The US Advisory Board
- Tenure: 0yrs
John Murphy (56yo)
Vice Chairman
- Tenure: 2.3yrs
- Compensation: €60.00k
Patrick Murphy (61yo)
Vice Chairman
- Tenure: 1.3yrs
- Compensation: €53.00k
Company Information
Glanbia plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Glanbia plc
- Ticker: GL9
- Exchange: ISE
- Founded: 1964
- Industry: Packaged Foods and Meats
- Sector: Food, Beverage & Tobacco
- Market Cap: €3.232b
- Shares outstanding: 295.17m
- Website: https://www.glanbia.com
Number of Employees
Location
- Glanbia plc
- Glanbia House
- Ring Road
- Kilkenny
- Co. Kilkenny
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GLB | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GL9 | ISE (Irish Stock Exchange) | Yes | Ordinary Shares | IE | EUR | Jan 1992 |
| GLAP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| GL9I | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GL9 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| GLBL | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GLB N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jan 1992 |
| GLAP.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Oct 1998 |
Biography
Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segmen ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 20:45 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/29 |
| Annual Earnings | 2018/12/29 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.